CD274 and cholangiocarcinoma: Following the results of the TOPAZ-1 trial, gemcitabine/cisplatin plus durvalumab received approval from the FDA and EMA and is now recommended in international guidelines as the new standard of care for the first-line treatment of locally advanced or metastatic CCA, irrespective of PD1/PD-L1 or MSI status.